Key facts
- This page summarizes George A. Eldridge's Form 3 filing for Aerovate Therapeutics, Inc. (JBIO).
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Jun 2021, 19:39.
George A. Eldridge - 29 Jun 2021 Form 3 Insider Report for Aerovate Therapeutics, Inc. (JBIO)
- Reporting relationship
- Officer Title: Chief Financial Officer and Treasurer Exhibit 24 - Power of Attorney
- Issuer ticker
- JBIO
- Reported as of
- 29 Jun 2021
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 29 Jun 2021, 19:39:34 UTC
- Prior SEC filing
- 01 Jul 2021
- Next SEC filing
- 16 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ George A. Eldridge
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
George A. Eldridge filed Form 3 for Aerovate Therapeutics, Inc. (JBIO) on 29 Jun 2021.
Change
- Previous filing in this sequence was filed on 01 Jul 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AVTE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,850
- Exercise price
- $2.14
- Footnotes
- F1
AVTE
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 29 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 98,676
- Exercise price
- $2.14
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
25% of this option shall vest and become exercisable on March 22, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
Footnote F2
25% of this option shall vest and become exercisable on June 4, 2022, with the remainder vesting in 36 substantially equal monthly installments thereafter.
SEC remarks
Officer Title: Chief Financial Officer and Treasurer Exhibit 24 - Power of Attorney